Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 14/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12727237 | 1.00 | SLC29A1 (0.51) | SLC29A1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL12727239 | 1.00 | SLC29A1 (0.51) | SLC29A1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2844589 | 0.86 | SLC29A1 (0.50) | SLC29A1ALDH1A1KMT2ATSHR | |
| SCHEMBL2844587 | 0.85 | SLC29A1 (0.57) | SLC29A1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2841760 | 0.82 | SLC29A1 (0.49) | SLC29A1ALDH1A1KMT2ATSHR | |
| SCHEMBL2841753 | 0.81 | SLC29A1 (0.57) | SLC29A1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL2835529 | 0.78 | SLC29A1 (0.48) | SLC29A1KMT2A | |
| SCHEMBL2835526 | 0.78 | SLC29A1 (0.54) | SLC29A1MAPTSMN1; SMN2LMNAALDH1A1 | |
| SCHEMBL17817154 | 0.76 | SLC29A1 (0.67) | SLC29A1KMT2A | |
| SCHEMBL2838660 | 0.74 | SLC29A1 (0.47) | SLC29A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098363-A1 | AMPHIPHILIC MOLECULES WITH A TRIAZINE CORE | BASF SE (DE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098363-A1 | AMPHIPHILIC MOLECULES WITH A TRIAZINE CORE | PAM, ABCB4, PAOX | SLC29A1 3588/4885MAPT 4141/4885SMN1; SMN2 4759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.